GET DAILY SIGNALSNeurogene Inc. (NGNE) Analyst Targets Suggest +220% Upside Potential
Key Takeaways
- The $75 central price target represents the arithmetic mean of eight verified analyst price targets and is not a guarantee or official consensus.
- At a recent price near $23.44, reaching $75 would require roughly a 220% advance, a substantial move even for a high-beta biotech stock.
- Individual analyst targets range widely from about $46 to $166, highlighting real differences in views on NGN-401's prospects.
- Supportive elements include durable Phase 1/2 data, a fully dosed pivotal trial, and a cash runway extending into early 2029.
- The primary risk remains binary, with pivotal Embolden trial results expected in the second half of 2027 likely deciding whether the target becomes attainable.
- For additional detail on the company's Major News, Today's Price Move, Forecast, and Earnings, review the dedicated pages.
- To explore AI-driven ideas across the market, check out Trending AI Robots.
Analyst Price Targets and Consensus View
Neurogene Inc. (NGNE) focuses on gene therapies for rare neurological conditions, with NGN-401 as the lead program for Rett syndrome. As a pre-revenue company, its valuation hinges primarily on clinical and regulatory progress rather than current earnings. I reviewed eight current analyst price targets that span from roughly $46 to $166, yielding an arithmetic mean near $75.4, which rounds to a central target of $75. All eight ratings are Buy, Outperform, or Overweight, and third-party trackers label the group a "Strong Buy," even as the spread in targets reveals meaningful divergence in outlook.
Recent moves underscore the differences. H.C. Wainwright adjusted its target to $60 from $65 in November 2026, pointing to a higher statistical success bar for the Embolden pivotal trial. JPMorgan started coverage with an Overweight rating and a $60 target in October 2026. Guggenheim lifted its target to $81 from $69 in August 2026, whereas Canaccord Genuity, at the more optimistic end, reduced its target to $166 from $180. Stifel holds the lower end at $46, while UBS and Rodman & Renshaw each set $70 targets in June 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares recently traded near $23.44 after pulling back from about $26 in early November and sitting well below the 52-week high near $43.66. Achieving the $75 target would call for approximately a 220% advance, a sizable move that would depend on clinical success more than steady operational gains. The realistic route is catalyst-driven. Neurogene Inc. (NGNE)'s core asset is NGN-401, a one-time AAV9 gene therapy delivering the MECP2 gene via the company's EXACT transgene regulation technology. The pivotal Embolden trial is fully dosed with 25 patients, and top-line data are expected in the second half of 2027. Management has outlined a 12-month Biologics License Application strategy and a potential path to commercialization. Success in Embolden could support a re-rating toward higher targets; a miss could erase much of the premium.
What Could Support a Move Toward the Target
- Phase 1/2 data demonstrated durable, multi-domain developmental gains, with 47 total milestones across 10 participants and no plateau or milestone loss through roughly 30 months of follow-up.
- The pivotal Embolden trial reached full dosing at 25 participants, exceeding the original target thanks to strong demand from the Rett syndrome community, with no HLH cases reported at the chosen dose.
- Cash, equivalents, and short-term investments of about $359.7 million are projected to support operations into the first quarter of 2029, reducing near-term financing pressure.
- NGN-401 carries Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA.
What Could Prevent the Target From Being Reached
- The Embolden pivotal trial represents a binary event; statistical success requires 9 of 25 responders (36%), a threshold some analysts view as having increased and that prompted certain target reductions.
- The company remains pre-revenue and loss-making, having relied at times on equity offerings that dilute existing shareholders.
- Gene therapies involve safety and manufacturing risks, and any toxicity signal could sharply lower the share price.
- The stock trades below both its 50-day and 200-day moving averages, reflecting softer near-term momentum.
Technical Levels and Market Structure
NGNE's 52-week range runs from roughly $15.93 to $43.66. Shares recently hovered near $23.44, below the 50-day moving average near $29 and the 200-day moving average near $28. Overhead resistance sits in the $26–$29 zone, where the stock consolidated earlier, followed by the $43.66 prior high. On the downside, the $20 psychological level and the $15.93 low mark important support areas. From what I see, these levels help frame risk management around the upcoming catalysts.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month horizon, yet for a clinical-stage biotech the clinical calendar matters most. Investors should track Embolden top-line results in the second half of 2027, further Phase 1/2 follow-up data, BLA submission timing, cash runway updates, and any analyst target changes. Regulatory feedback from the FDA and competitive developments in Rett syndrome treatment also warrant attention. I’m watching this closely as the data readout approaches.
Final Assessment
Whether Neurogene Inc. (NGNE) can reach $75 ultimately hinges on NGN-401's pivotal data rather than short-term trading dynamics. The central target, calculated as the mean of eight analyst targets, lies well above the recent price and implies a roughly 220% gain that would require Embolden success and progress toward a BLA. Bullish analysts highlight durable Phase 1/2 efficacy, full enrollment in the pivotal trial, and a solid cash runway, while more cautious voices emphasize the binary outcome, a higher success threshold, and ongoing dilution. With targets spanning roughly $46 to $166, the dispersion suggests treating the $75 figure as a directional benchmark rather than a precise destination. The pivotal data in the second half of 2027 stands as the single most important event ahead.
Exploring AI Daily Buy/Sell Signals for Biotech Stocks
In my own research process, I sometimes turn to Tickeron's AI Daily Buy/Sell Signals to monitor how shifting market conditions and technical factors align with fundamental views on names like NGNE. The platform applies artificial intelligence across thousands of stocks and ETFs to generate Buy, Sell, or Hold signals, which can help surface opportunities and track evolving trends more efficiently alongside clinical analysis. For a catalyst-heavy stock, these signals offer one additional lens when forming an overall perspective.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NGNE's Stochastic Oscillator remains in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NGNE's RSI Indicator exited the oversold zone, 29 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +3.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where NGNE advanced for three days, in 235 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NGNE as a result. In 78 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for NGNE turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NGNE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NGNE broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NGNE entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. NGNE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.333) is normal, around the industry mean (3.498). P/E Ratio (-5.022) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (416.667) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NGNE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement